Table 1: Categorization of residents, their status, rights, obstacles and restrictions7
Category
|
Status
|
Rights
|
Obstacles/Legal restrictions
|
Permanent residents (KT1)
|
Residents (including both non-migrants and migrants) with permanent household registration at place of current residence.
|
· Purchase and sell land and housing and have land/house ownership certificates
· Access to public facilities and social services at current place of residence
· Access to formal financial loans
· Access to employment
|
· Access to public social services including education and health care only within their district of residence
|
Intra-province migrants (KT2)
|
Migrants who have permanent household registration in the province/city of current residence;
|
· Purchase and sell land and housing and have land/house ownership certificates.
· Access to public facilities and social services
· Access to formal financial loans
· Access to employment
|
· Access to education and health care only within the district where they are registered
· Lack of access to financial loans/formal financial services
|
Long-term, inter-province migrants (KT3)
|
Migrants who do not have permanent registration at the place of current residence but have temporary registration for 6-12 months with the possibility of extension;
|
· Access to public facilities and social services
|
· Lack of access to legal housing
· KT3 children can go to public schools only when they are not used to full capacity (by KT1 and KT2 children). If the schools are overcrowded, KT3 children must attend private schools, where they have to pay higher school fees
· Lack of access to financial loans/formal financial services
|
Short-term, inter-province migrants (KT4)
|
Migrants who do not have permanent registration at the place of current residence but have temporary registration for 1-6 months
|
Do not have the right to purchase land and access to public social services and financial loans
|
|
Unregistered residents
|
Those who do not belong to any of the above category
|
Do not have the right to purchase land and access to public social services and financial loans
|
|
Table 2: Sample characteristics of notified TB cases by residency
|
Total
N (%)
|
Permanent residents, KT1
N (%)
|
Intra-province, KT2
N (%)
|
Long-term, inter-province KT3
N (%)
|
Short-term, inter-province KT4
N (%)
|
Temporary residents, KT2-KT4
N (%)
|
Total
|
5,502 (100)
|
4,258 (77)
|
170 (3)
|
340 (6)
|
734 (13)
|
1,244 (23)
|
Sex
|
|
|
|
|
|
|
Male
|
3,791 (69)
|
3,000 (70)
|
107 (63)
|
230 (68)
|
454 (62)
|
791 (64)
|
Female
|
1,711 (31)
|
1,258 (30)
|
63 (37)
|
110 (32)
|
280 (38)
|
453 (36)
|
Age
|
|
|
|
|
|
|
<25 years
|
829 (15)
|
529 (12)
|
29 (17)
|
62 (18)
|
209 (29)
|
300 (24)
|
25-34 years
|
1,331 (24)
|
906 (21)
|
44 (26)
|
108 (32)
|
273 (37)
|
425 (34)
|
35-44 years
|
1,123 (20)
|
904 (21)
|
33 (19)
|
65 (19)
|
121 (17)
|
219 (18)
|
45-54 years
|
1,120 (20)
|
953 (22)
|
30 (18)
|
66 (19)
|
71 (10)
|
167 (13)
|
>55 years
|
1,087 (20)
|
955 (22)
|
34 (20)
|
39 (11)
|
59 (8)
|
132 (11)
|
Treatment outcome
|
|
|
|
|
|
|
Success
|
4,630 (84)
|
3,587 (85)
|
137 (81)
|
295 (87)
|
611 (83)
|
1,043 (83)
|
Cure
|
2,598 (47)
|
2,032 (48)
|
75 (44)
|
172 (51)
|
319 (43)
|
566 (46)
|
Complete
|
2,032 (37)
|
1,555 (37)
|
62 (36)
|
123 (36)
|
292 (40)
|
477 (38)
|
LTFU
|
262 (5)
|
179 (4)
|
13 (8)
|
9 (3)
|
61 (8)
|
83 (7)
|
Failure
|
225 (4)
|
188 (4)
|
8 (5)
|
16 (5)
|
13 (2)
|
37 (3)
|
Death
|
232 (4)
|
207 (5)
|
5 (3)
|
11 (3)
|
9 (1)
|
25 (2)
|
Transfer out
|
153 (3)
|
97 (2)
|
7 (4)
|
9 (3)
|
40 (5)
|
56 (5)
|
Patient type┼
|
|
|
|
|
|
|
New
|
4,301 (78)
|
3261 (21)
|
143 (84)
|
277 (81)
|
620 (84)
|
1,040 (84)
|
Relapse
|
527 (10)
|
459 (11)
|
13 (8)
|
17 (5)
|
38 (5)
|
68 (5)
|
Failure
|
100 (2)
|
85 (2)
|
1 (1)
|
8 (2)
|
6 (1)
|
15 (1)
|
LTFU
|
55 (1)
|
44 (1)
|
2 (1)
|
2 (1)
|
7 (1)
|
11 (1)
|
Unknown
|
311 (6)
|
256 (6)
|
5 (3)
|
22 (6)
|
27 (4)
|
55 (4)
|
Transfer in
|
208 (4)
|
153 (4)
|
6 (4)
|
14 (4)
|
35 (5)
|
55 (4)
|
Type of TB§
|
|
|
|
|
|
|
AFB(+)
|
3,205 (34)
|
2,500 (59)
|
94 (55)
|
208 (61)
|
403 (55)
|
705 (57)
|
AFB(−)
|
1,096 (22)
|
862 (20)
|
38 (22)
|
66 (19)
|
130 (18)
|
234 (19)
|
EP
|
1,201 (25)
|
896 (21)
|
38 (22)
|
66 (19)
|
201 (27)
|
305 (25)
|
HIV/AIDS ¶
|
|
|
|
|
|
|
No/Unknown
|
4,886 (89)
|
3,761 (88)
|
144 (85)
|
310 (91)
|
671 (91)
|
1,125 (90)
|
Yes
|
616 (11)
|
497 (12)
|
26 (15)
|
30 (9)
|
63 (9)
|
119 (10)
|
Diabetes mellitus
|
|
|
|
|
|
|
No/Unknown
|
5,169 (94)
|
3,976 (93)
|
160 (94)
|
321 (94)
|
712 (97)
|
1,193 (96)
|
Yes
|
333 (6)
|
282 (7)
|
10 (6)
|
19 (6)
|
22 (3)
|
51 (4)
|
Notes:
┼ Failure = Retreatment after CAT I treatment failure; LTFU = Retreatment after loss to follow-up; Unknown = Retreatment with unknown/uncertain exposure to anti-TB drugs;
- AFB(+)=Sputum smear positive; AFB(−)=Sputum smear negative; EP=Extra-pulmonary TB;
¶ Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome;
Table 3: Crude associations of residency and secondary exposures with treatment success and loss to follow-up (n=5,502)
|
Treatment success
|
Loss to follow-up
|
|
RR‡
|
95% CI
|
p-valueÞ
|
OR‡
|
95% CI
|
p-valueÞ
|
Total
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
Residency
|
|
|
|
|
|
|
Permanent¥
|
1.00
|
|
|
1.00
|
|
|
Temporary
|
1.00
|
[0.97, 1.02]
|
0.736
|
1.63
|
[1.25, 2.13]
|
<0.001
|
Residency
|
|
|
|
|
|
|
KT1¥
|
1.00
|
|
|
1.00
|
|
|
KT2
|
0.96
|
[0.89, 1.03]
|
0.246
|
1.89
|
[1.05, 3.39]
|
0.033
|
KT3
|
1.03
|
[0.99, 1.08]
|
0.184
|
0.62
|
[0.31, 1.22]
|
0.167
|
KT4
|
0.99
|
[0.95, 1.02]
|
0.504
|
2.07
|
[1.53, 2.79]
|
<0.001
|
Sex
|
|
|
|
|
|
|
Male¥
|
1.00
|
|
|
1.00
|
|
|
Female
|
1.05
|
[1.03, 1.08]
|
<0.001
|
0.78
|
[0.59, 1.04]
|
0.089
|
Age
|
|
|
|
|
|
|
<25 years¥
|
1.00
|
|
|
1.00
|
|
|
25-34 years
|
0.95
|
[0.91, 0.98]
|
0.001
|
1.23
|
[0.86, 1.78]
|
0.260
|
35-44 years
|
0.96
|
[0.92, 0.99]
|
0.015
|
0.84
|
[0.56, 1.26]
|
0.410
|
45-54 years
|
0.97
|
[0.94, 1.00]
|
0.071
|
0.58
|
[0.37, 0.91]
|
0.016
|
>55 years
|
0.91
|
[0.87, 0.94]
|
<0.001
|
0.55
|
[0.35, 0.86]
|
0.010
|
Patient type┼
|
|
|
|
|
|
|
New¥
|
1.00
|
|
|
1.00
|
|
|
Relapse
|
0.86
|
[0.82, 0.91]
|
<0.001
|
1.02
|
[0.66, 1.58]
|
0.925
|
Failure
|
0.61
|
[0.51, 0.73]
|
<0.001
|
1.61
|
[0.74, 3.52]
|
0.232
|
LTFU
|
0.82
|
[0.69, 0.97]
|
0.019
|
2.14
|
[0.84, 5.43]
|
0.109
|
Unknown
|
0.94
|
[0.89, 0.99]
|
0.018
|
1.39
|
[0.86, 2.26]
|
0.182
|
Transfer in
|
0.85
|
[2.05, 2.93]
|
<0.001
|
1.66
|
[0.96, 2.87]
|
0.067
|
Type of TB§
|
|
|
|
|
|
|
AFB(+)¥
|
1.00
|
|
|
1.00
|
|
|
AFB(−)
|
1.09
|
[1.06, 1.12]
|
<0.001
|
0.78
|
[0.55, 1.09]
|
0.143
|
EP
|
1.07
|
[1.04, 1.10]
|
<0.001
|
0.87
|
[0.64, 1.20]
|
0.398
|
HIV/AIDS¶
|
|
|
|
|
|
|
No/Unknown¥
|
1.00
|
|
|
1.00
|
|
|
Yes
|
0.78
|
[0.74, 0.83]
|
<0.001
|
2.56
|
[1.90, 3.46]
|
<0.001
|
Diabetes
|
|
|
|
|
|
|
No/Unknown¥
|
1.00
|
|
|
1.00
|
|
|
Yes
|
0.96
|
[0.91, 1.01]
|
0.145
|
0.87
|
[0.50, 1.51]
|
0.622
|
Notes:
‡ Crude Risk Ratios and Odds Ratios calculated by univariate log binomial and logistic regression, respectively;
Þ Wald test;
¥ Referent;
┼ Failure = Retreatment after CAT I treatment failure; LTFU = Retreatment after loss to follow-up; Unknown = Retreatment with unknown/uncertain exposure to anti-TB drugs;
- AFB(+)=Sputum smear positive; AFB(−)=Sputum smear negative; EP=Extra-pulmonary TB;
¶ Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome;
Table 4: Crude associations of residency and secondary exposures with treatment success and loss to follow-up (n=5,490)
|
Treatment success
|
Loss to follow-up
|
|
aRR‡
|
95% CI
|
p-valueÞ
|
aOR‡
|
95% CI
|
p-valueÞ
|
Residency
|
|
|
|
|
|
|
KT1¥
|
1.00
|
|
|
1.00
|
|
|
KT2
|
0.95
|
[0.88, 1.02]
|
0.163
|
1.86
|
[1.03, 3.36]
|
0.041
|
KT3
|
1.01
|
[0.97, 1.05]
|
0.685
|
0.59
|
[0.30, 1.17]
|
0.134
|
KT4
|
0.95
|
[0.92, 0.99]
|
0.010
|
1.98
|
[1.44, 2.72]
|
<0.001
|
Sex
|
|
|
|
|
|
|
Male¥
|
1.00
|
|
|
1.00
|
|
|
Female
|
1.02
|
[1.00, 1.05]
|
0.078
|
0.80
|
[0.60, 1.07]
|
0.139
|
Age
|
|
|
|
|
|
|
<25 years¥
|
1.00
|
|
|
1.00
|
|
|
25-34 years
|
1.00
|
[0.97, 1.04]
|
0.881
|
1.00
|
[0.68, 1.46]
|
0.982
|
35-44 years
|
1.01
|
[0.97, 1.04]
|
0.622
|
0.73
|
[0.48, 1.11]
|
0.142
|
45-54 years
|
1.00
|
[0.96, 1.03]
|
0.863
|
0.59
|
[0.37, 0.93]
|
0.024
|
>55 years
|
0.93
|
[0.89, 0.96]
|
<0.001
|
0.58
|
[0.36, 0.93]
|
0.024
|
Patient type┼
|
|
|
|
|
|
|
New¥
|
1.00
|
|
|
1.00
|
|
|
Relapse
|
0.89
|
[0.84, 0.94]
|
<0.001
|
1.09
|
[0.69, 1.73]
|
0.705
|
Failure
|
0.62
|
[0.52, 0.75]
|
<0.001
|
1.77
|
[0.80, 3.95]
|
0.160
|
LTFU
|
0.87
|
[0.73, 1.02]
|
0.085
|
1.79
|
[0.69, 4.62]
|
0.228
|
Unknown
|
0.97
|
[0.92, 1.02]
|
0.198
|
1.42
|
[0.86, 2.36]
|
0.171
|
Transfer in
|
0.88
|
[0.81, 0.96]
|
0.003
|
1.48
|
[0.85, 2.60]
|
0.170
|
Type of TB§,Π
|
|
|
|
|
|
|
AFB(+)¥
|
1.00
|
|
|
1.00
|
|
|
AFB(−)
|
1.06
|
[1.03, 1.09]
|
<0.001
|
0.79
|
[0.55, 1.12]
|
0.184
|
EP
|
1.05
|
[1.02, 1.08]
|
0.001
|
0.77
|
[0.55, 1.08]
|
0.126
|
HIV/AIDS¶
|
|
|
|
|
|
|
No/Unknown¥
|
1.00
|
|
|
1.00
|
|
|
Yes
|
0.77
|
[0.73, 0.82]
|
<0.001
|
2.18
|
[1.55, 3.06]
|
<0.001
|
Diabetes
|
|
|
|
|
|
|
No/Unknown¥
|
1.00
|
|
|
1.00
|
|
|
Yes
|
0.96
|
[0.91, 1.02]
|
0.159
|
1.15
|
[0.65, 2.03]
|
0.619
|
|
|
|
|
|
|
|
|
Notes:
‡ Adjusted summary RR/OR by log binomial and logistic regression adjusted by all other variables listed in the table;
Þ Wald test;
¥ Referent;
┼ Failure = Retreatment after CAT I treatment failure; LTFU = Retreatment after loss to follow-up; Unknown = Retreatment with unknown/uncertain exposure to anti-TB drugs;
- AFB(+)=Sputum smear positive; AFB(−)=Sputum smear negative; EP=Extra-pulmonary TB;
Π not included in the final convergent multivariate model with LTFU as the primary outcome
¶ Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome;
Table 5: Comparative interrupted time series analysis of monthly treatment success and loss to follow-up rates
|
Treatment success
|
Loss to follow-up
|
|
IRR┼
|
95% CI
|
p-valueÞ
|
IRR‡
|
95% CI
|
p-valueÞ
|
Baseline rate (β0)¥
|
0.85
|
[0.83, 0.87]
|
<0.001
|
0.05
|
[0.03, 0.09]
|
<0.001
|
Pre-intervention trend, control (β1)
|
1.00
|
[1.00, 1.00]
|
0.624
|
0.96
|
[0.92, 0.99]
|
0.024
|
Post-intervention step change, control (β2)
|
1.00
|
[0.97, 1.03]
|
0.971
|
2.41
|
[0.97, 6.00]
|
0.059
|
Post-intervention trend, control (β3)
|
1.00
|
[1.00, 1.00]
|
0.382
|
1.04
|
[1.00, 1.09]
|
0.050
|
Difference in baseline (β4)
|
1.00
|
[0.95, 1.05]
|
0.909
|
1.91
|
[0.97, 3.76]
|
0.060
|
Difference in pre-intervention trends (β5)
|
1.00
|
[1.00, 1.00]
|
0.541
|
1.02
|
[0.98, 1.07]
|
0.305
|
Difference in post-intervention step change (β6)
|
1.07
|
[1.00, 1.15]
|
0.041
|
0.17
|
[0.04, 0.69]
|
0.013
|
Difference in post-intervention trends (β7)
|
1.00
|
[1.00, 1.00]
|
0.435
|
0.90
|
[0.83, 0.98]
|
0.019
|
Notes:
All patients in intervention and control districts, January 2011 to March 2017
¥ The parameters were obtained for a segmented regression model with the following structure: . Here Yt is the outcome measure along time t; Tt is the monthly time counter; Xt indicates pre- and post-intervention periods, Z denotes the intervention cohort, and ZTt, ZXt, and ZXtTt are interaction terms. β0 to β3 relate to the control group as follows: β0, intercept; β1, pre-intervention slope; β2, post-intervention step change; β3, post-intervention trend. β4 to β7 represent differences between the control and intervention districts: β4, difference in baseline intercepts; β5, difference in pre-intervention trends; β6, difference in post-intervention step changes; β7, post-intervention trend difference.
┼ IRR based on log-linear Poisson regression with robust standard error estimations;
‡ IRR based on log-linear GEE Poisson regression with an autoregressive correlation structure with lag order 2;
Þ Wald test;